Posted by Michael Wonder on 10 May 2019
Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds
9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting.
The Institute for Clinical and Economic Review today released an evidence report assessing the comparative clinical effectiveness and value of esketamine (Spravato, Janssen), a nasal spray approved by the FDA in March as a therapy for treatment-resistant depression (TRD).
Esketamine is one of the two mirror-image molecules (enantiomers) that make up ketamine, an anesthetic that is commonly used off-label to treat TRD.
